Talk:Programmed death-ligand 1 - Revision history

Michael at 15:26, 29 October 2024

2024-10-29T15:26:26Z

← Older revision		Revision as of 15:26, 29 October 2024
Line 13:		Line 13:
	CPS in lymph nodes:		CPS in lymph nodes:
	*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/		*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
			*H&N cytology: https://pmc.ncbi.nlm.nih.gov/articles/PMC8810615/
	*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z		*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

Michael at 15:22, 29 October 2024

2024-10-29T15:22:40Z

← Older revision		Revision as of 15:22, 29 October 2024
Line 12:		Line 12:

	CPS in lymph nodes:		CPS in lymph nodes:
	https://pubmed.ncbi.nlm.nih.gov/35420378/		*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
	https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/		*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z
	https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/
	https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

Michael at 15:19, 29 October 2024

2024-10-29T15:19:55Z

← Older revision		Revision as of 15:19, 29 October 2024
Line 9:		Line 9:
	*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922]		*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922]

			==CPS and TPS==

			CPS in lymph nodes:
			https://pubmed.ncbi.nlm.nih.gov/35420378/
			https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
			https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/
			https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

Michael at 13:16, 17 February 2018

2018-02-17T13:16:38Z

← Older revision		Revision as of 13:16, 17 February 2018
Line 7:		Line 7:
	*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]		*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
	*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]		*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]
			*2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[https://www.ncbi.nlm.nih.gov/pubmed/29362922]


	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

Michael at 13:14, 17 February 2018

2018-02-17T13:14:16Z

← Older revision		Revision as of 13:14, 17 February 2018
Line 7:		Line 7:
	*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]		*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
	*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]		*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]



			==References==
			{{Reflist\|1}}

Michael at 13:13, 17 February 2018

2018-02-17T13:13:55Z

← Older revision		Revision as of 13:13, 17 February 2018
Line 1:		Line 1:
			==Urothelial carcinoma==
	Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal \| last1 = Rosenberg \| first1 = JE. \| last2 = Hoffman-Censits \| first2 = J. \| last3 = Powles \| first3 = T. \| last4 = van der Heijden \| first4 = MS. \| last5 = Balar \| first5 = AV. \| last6 = Necchi \| first6 = A. \| last7 = Dawson \| first7 = N. \| last8 = O'Donnell \| first8 = PH. \| last9 = Balmanoukian \| first9 = A. \| title = Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. \| journal = Lancet \| volume = 387 \| issue = 10031 \| pages = 1909-20 \| month = May \| year = 2016 \| doi = 10.1016/S0140-6736(16)00561-4 \| PMID = 26952546 }}</ref>		Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal \| last1 = Rosenberg \| first1 = JE. \| last2 = Hoffman-Censits \| first2 = J. \| last3 = Powles \| first3 = T. \| last4 = van der Heijden \| first4 = MS. \| last5 = Balar \| first5 = AV. \| last6 = Necchi \| first6 = A. \| last7 = Dawson \| first7 = N. \| last8 = O'Donnell \| first8 = PH. \| last9 = Balmanoukian \| first9 = A. \| title = Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. \| journal = Lancet \| volume = 387 \| issue = 10031 \| pages = 1909-20 \| month = May \| year = 2016 \| doi = 10.1016/S0140-6736(16)00561-4 \| PMID = 26952546 }}</ref>

			==Renal cell carcinoma==
			*2015 paper: ~ 15% respond to PD-L1[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647139/]
			**Biomarkers predict response
			*2018 paper: ~ 70% durable response among those that discontinue d/t side effects[https://www.ncbi.nlm.nih.gov/pubmed/29437040]
			*2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[https://www.ncbi.nlm.nih.gov/pubmed/29368638]

Michael: Created page with "Urothelial carcinoma - atezolizumab{{Cite journal | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3..."

2016-07-10T19:55:48Z

Created page with "Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3..."

New page

Urothelial carcinoma - atezolizumab<ref name=pmid26952546>{{Cite journal | last1 = Rosenberg | first1 = JE. | last2 = Hoffman-Censits | first2 = J. | last3 = Powles | first3 = T. | last4 = van der Heijden | first4 = MS. | last5 = Balar | first5 = AV. | last6 = Necchi | first6 = A. | last7 = Dawson | first7 = N. | last8 = O'Donnell | first8 = PH. | last9 = Balmanoukian | first9 = A. | title = Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | journal = Lancet | volume = 387 | issue = 10031 | pages = 1909-20 | month = May | year = 2016 | doi = 10.1016/S0140-6736(16)00561-4 | PMID = 26952546 }}</ref>